Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections

Table 1

Demographics of patients receiving intrapleural therapy.

	Standard IPFT	Extended IPFT	value
Patients ()	81	20
Age (years)
Median [interquartile range (25–75)]	62 44–74	57 49–64	0.394
Sex ()			0.648
Male	44	12
Female	37	8
Body mass index (kg/m^2)
Median [interquartile range (25–75)]	25 22–31	22 21–25	0.097
RAPID pleural infection score
Mean [standard deviation]	3.0 1.5	2.7 1.4	0.564
Etiology of infection (, (%))			0.616
Primary	64	16
Bacteremia	8	3
Postthoracic surgery	9	0
Other	0	1
Hospital acquired infection (, (%))	18 (22)	10 (50)	0.013
Median pleural fluid characteristics [interquartile range (25–75)]
Lactate dehydrogenase (units/L)	1118 541–4117	827 484–6261	0.980
Protein (g/dL)	4 3-4	3 3-4	0.561
Glucose (mg/dL)	69 25–92	57 32–81	0.652
Pleural fluid microbiology analysis
Gram stain, positive (, (%))	27 (33)	8 (40)	0.575
Fluid culture, positive ( (%))	29 (36)	15 (75)	0.002